A Phase 3 interventional study of AG-013736 and Gemcitabine in Carcinoma, Pancreatic Ductal, sponsored by Pfizer. Completed at 205 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Carcinoma, Pancreatic Ductal with a site in United States — 5 open to participants now, 10 under way, 1 of them phase 3. Carcinoma, Pancreatic Ductal · United States.
Among the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2007, is one of 4 in phase 3, and was the 2nd registered.
57 studies on the registry are indexed under Carcinoma, Pancreatic Ductal; 10 are open to participants now.
Browse Carcinoma, Pancreatic Ductal studies →5 of the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States are open now. Recruiting first, the newest first:
Corcept Therapeutics · Sites in United States
Ages 18+
EXACT Therapeutics AS · Sites in United States, United Kingdom
Ages 18+
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, France, Germany and 4 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Carcinoma, Pancreatic Ductal studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 630 is above the median of 72 across 44 interventional studies indexed under Carcinoma, Pancreatic Ductal.
Median enrollment 97 across the 26 interventional studies, 51 across the 4 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Carcinoma, Pancreatic Ductal — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Pancreatic Ductal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06850623EXACT Therapeutics ASAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | 2026-12-15 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05379985Revolution Medicines, Inc.Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | 2027-05-31 |
| NCT07259317Corcept TherapeuticsRelacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG-013736 · Drug: Gemcitabine
Drug: Gemcitabine · Drug: placebo
oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
placebo
Overall Survival (OS)
Time in weeks from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline until death or at least 1 year after the randomization of last participant
Progression Free Survival (PFS)
Time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline until disease progression or at least 1 year after the randomization of last participant
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
Time frame: Baseline, every 8 weeks until tumor progression or death
Duration of Response (DR)
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.
Time frame: Baseline until death or at least 1 year after the randomization of last participant
Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.
Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score
QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.
Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Change From Baseline Brief Pain Inventory-short Form (BPI-sf) Score
BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal
Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 23 months
| Milestone | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Started | 314 | 316 |
| Treated | 305 | 308 |
| Completed | 142 | 142 |
| Not completed | 172 | 174 |
| Withdrew: Adverse event | 32 | 33 |
| Withdrew: Withdrawal by subject | 14 | 11 |
| Withdrew: Death | 11 | 12 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Objective progression or relapse | 84 | 87 |
| Withdrew: Global deterioration of health status | 12 | 14 |
| Withdrew: Randomized but not treated | 9 | 8 |
| Withdrew: Other | 4 | 5 |
Time in weeks from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| Weeks | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Overall Survival (OS) | 36.9 (30.1 to 41.1) | 35.8 (30.0 to 44.8) |
Time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Weeks | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Progression Free Survival (PFS) | 19.1 (17.1 to 24.4) | 18.9 (16.2 to 22.6) |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
| Percentage of participants | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Percentage of Participants With Objective Response (OR) | 4.9 (2.5 to 8.3) | 1.6 (0.4 to 4.0) |
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.
| Weeks | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Duration of Response (DR) | 33.1 (16.1 to 33.1) | NA (NA to NA) |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.
| Units on a scale | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Physical functioning: Baseline (n=295, 289) | 77.445 ± 20.3052 | 78.546 ± 18.9192 |
| Physical functioning: Change at C2 D1 (n=233, 233) | -2.713 ± 16.7682 | -3.261 ± 15.0742 |
| Physical functioning: Change at C3 D1 (n=173, 179) | -5.897 ± 19.3522 | -1.565 ± 16.2738 |
| Physical functioning: Change at C4 D1 (n=134, 133) | -5.671 ± 18.8623 | -1.453 ± 17.1209 |
| Physical functioning: Change at C5 D1 (n=96, 82) | -2.498 ± 21.8687 | -0.076 ± 16.9709 |
| Physical functioning: Change at C6 D1 (n=59, 58) | -5.193 ± 19.6995 | -1.719 ± 15.5260 |
| Physical functioning: Change at C7 D1 (n=38, 37) | -1.924 ± 14.2726 | 0.011 ± 18.9261 |
| Physical functioning: Change at C8 D1 (n=15, 21) | -4.000 ± 16.8759 | 0.014 ± 13.8428 |
| Physical functioning: Change at C9 D1 (n=9, 9) | 0.033 ± 15.2534 | -12.578 ± 20.9490 |
| Physical functioning: Change at C10 D1 (n=3, 4) | 6.667 ± 17.5754 | -1.675 ± 22.0563 |
| Physical functioning: Change at C11 D1 (n=1, 1) | 0.000 ± NA | -6.600 ± NA |
| Physical functioning: Change at C12 D1 (n=1, 0) | 0.000 ± NA | NA ± NA |
| Physical functioning: Change at C13 D1 (n=1, 0) | 0.000 ± NA | NA ± NA |
| Physical functioning:Change at followup (n=67, 70) | -17.713 ± 23.8263 | -11.523 ± 21.0513 |
| Role functioning: Baseline (n=297, 295) | 66.3 ± 30.09 | 68.1 ± 30.72 |
| Role functioning: Change at C2 D1 (n=239, 242) | -2.2 ± 30.95 | -2.8 ± 25.75 |
| Role functioning: Change at C3 D1 (n=177, 185) | -4.6 ± 32.65 | 1.5 ± 26.90 |
| Role functioning: Change at C4 D1 (n=135, 136) | -4.3 ± 32.13 | 1.2 ± 27.18 |
| Role functioning: Change at C5 D1 (n=99, 81) | -0.5 ± 34.95 | -2.7 ± 29.63 |
| Role functioning: Change at C6 D1 (n=60, 58) | -4.4 ± 29.25 | -2.3 ± 24.27 |
| Role functioning: Change at C7 D1 (n=38, 37) | -3.1 ± 25.07 | -1.3 ± 26.75 |
| Role functioning: Change at C8 D1 (n=16, 21) | -6.2 ± 20.05 | 0.0 ± 31.63 |
| Role functioning: Change at C9 D1 (n=9, 9) | 1.9 ± 28.21 | -20.4 ± 33.11 |
| Role functioning: Change at C10 D1 (n=3, 4) | 5.6 ± 9.64 | -4.2 ± 28.46 |
| Role functioning: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -50.0 ± NA |
| Role functioning: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Role functioning: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Role functioning: Change at follow-up (n=66, 72) | -20.0 ± 31.52 | -14.1 ± 32.34 |
| Emotional functioning (EF): Baseline (n=294, 287) | 70.8 ± 22.01 | 71.7 ± 22.47 |
| EF: Change at C2 D1 (n=233, 229) | 5.0 ± 21.48 | 5.0 ± 18.92 |
| EF: Change at C3 D1 (n=170, 180) | 3.7 ± 20.19 | 3.4 ± 18.95 |
| EF: Change at C4 D1 (n=134, 131) | 3.0 ± 22.54 | 5.2 ± 21.12 |
| EF: Change at C5 D1 (n=96, 80) | 4.3 ± 21.09 | 5.9 ± 17.24 |
| EF: Change at C6 D1 (n=60, 56) | 4.0 ± 19.31 | 6.7 ± 17.43 |
| EF: Change at C7 D1 (n=37, 34) | 0.0 ± 18.84 | 3.2 ± 16.28 |
| EF: Change at C8 D1 (n=17, 19) | -2.9 ± 22.05 | 5.3 ± 14.74 |
| EF: Change at C9 D1 (n=9, 9) | 3.7 ± 16.72 | -4.6 ± 15.07 |
| EF: Change at C10 D1 (n=3, 4) | 13.9 ± 12.73 | 2.1 ± 18.50 |
| EF: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -16.6 ± NA |
| EF: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| EF: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| EF: Change at follow-up (n=65, 71) | -7.3 ± 23.51 | -2.7 ± 23.14 |
| Cognitive Functioning (CF): Baseline (n=293, 288) | 78.7 ± 22.26 | 80.9 ± 21.50 |
| CF: Change at C2 D1 (n=234, 234) | -1.1 ± 19.86 | -0.3 ± 17.74 |
| CF: Change at C3 D1 (n=172, 179) | -2.1 ± 20.43 | -0.9 ± 18.67 |
| CF: Change at C4 D1 (n=134, 134) | -4.2 ± 19.98 | 2.0 ± 18.62 |
| CF: Change at C5 D1 (n=97, 80) | -1.4 ± 20.21 | 1.7 ± 18.86 |
| CF: Change at C6 D1 (n=60, 56) | -3.1 ± 19.27 | -4.5 ± 19.97 |
| CF: Change at C7 D1 (n=38, 34) | -4.4 ± 18.45 | 0.5 ± 14.50 |
| CF: Change at C8 D1 (n=17, 17) | -8.8 ± 22.15 | -2.9 ± 23.74 |
| CF: Change at C9 D1 (n=9, 9) | -0.0 ± 25.03 | -1.8 ± 24.22 |
| CF: Change at C10 D1 (n=3, 4) | -5.6 ± 9.64 | 8.3 ± 28.88 |
| CF: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| CF: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| CF: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| CF: Change at follow-up (n=65, 71) | -12.6 ± 25.01 | -7.5 ± 25.47 |
| Social functioning: Baseline (n=289, 286) | 68.9 ± 27.98 | 69.7 ± 28.83 |
| Social functioning: Change at C2 D1 (n=232, 230) | 1.3 ± 24.73 | 0.9 ± 26.35 |
| Social functioning: Change at C3 D1 (n=169, 178) | -1.3 ± 29.38 | 3.2 ± 27.31 |
| Social functioning: Change at C4 D1 (n=132, 134) | 0.1 ± 25.51 | 0.6 ± 26.83 |
| Social functioning: Change at C5 D1 (n=95, 80) | 2.1 ± 27.31 | 0.8 ± 27.93 |
| Social functioning: Change at C6 D1 (n=58, 56) | -4.9 ± 28.79 | 1.5 ± 29.52 |
| Social functioning: Change at C7 D1 (n=37, 35) | -5.4 ± 20.05 | 2.4 ± 29.47 |
| Social functioning: Change at C8 D1 (n=17, 19) | 4.9 ± 29.91 | -1.7 ± 27.72 |
| Social functioning: Change at C9 D1 (n=9, 9) | -0.0 ± 32.29 | -1.8 ± 28.20 |
| Social functioning: Change at C10 D1 (n=3, 4) | 5.6 ± 9.64 | 12.5 ± 43.83 |
| Social functioning: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 33.4 ± NA |
| Social functioning: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Social functioning: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Social functioning: Change at follow-up (n=64, 70) | -13.3 ± 33.75 | -2.6 ± 33.88 |
| Fatigue: Baseline (n=293, 289) | 41.0 ± 23.87 | 40.1 ± 25.12 |
| Fatigue: Change at C2 D1 (n=227, 228) | 2.8 ± 21.15 | 2.1 ± 20.12 |
| Fatigue: Change at C3 D1 (n=170, 181) | 3.4 ± 21.94 | -0.9 ± 21.76 |
| Fatigue: Change at C4 D1 (n=132, 132) | 5.6 ± 23.97 | -1.1 ± 22.77 |
| Fatigue: Change at C5 D1 (n=97, 80) | -0.0 ± 24.39 | 1.1 ± 21.92 |
| Fatigue: Change at C6 D1 (n=60, 57) | 5.0 ± 21.31 | 0.0 ± 21.22 |
| Fatigue: Change at C7 D1 (n=38, 36) | 1.8 ± 20.61 | 2.2 ± 19.12 |
| Fatigue: Change at C8 D1 (n=17, 20) | 7.2 ± 22.89 | 4.4 ± 22.05 |
| Fatigue: Change at C9 D1 (n=9, 9) | -6.2 ± 21.63 | 14.8 ± 24.21 |
| Fatigue: Change at C10 D1 (n=3, 4) | -11.1 ± 19.28 | -5.5 ± 27.98 |
| Fatigue: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 11.1 ± NA |
| Fatigue: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Fatigue: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Fatigue: Change at follow-up (n=63, 71) | 13.1 ± 25.93 | 12.1 ± 25.95 |
| Nausea and vomiting: Baseline (n=295, 294) | 12.9 ± 19.19 | 13.1 ± 19.75 |
| Nausea and vomiting: Change at C2 D1 (n=238, 239) | 3.7 ± 20.69 | 2.9 ± 22.93 |
| Nausea and vomiting: Change at C3 D1 (n=176, 185) | 1.9 ± 20.38 | -0.4 ± 19.54 |
| Nausea and vomiting: Change at C4 D1 (n=133, 135) | 3.5 ± 20.82 | 0.4 ± 19.68 |
| Nausea and vomiting: Change at C5 D1 (n=98, 81) | 4.6 ± 22.16 | 1.0 ± 18.88 |
| Nausea and vomiting: Change at C6 D1 (n=60, 59) | 6.9 ± 22.61 | 2.8 ± 20.33 |
| Nausea and vomiting: Change at C7 D1 (n=38, 37) | 1.3 ± 19.52 | 2.7 ± 20.24 |
| Nausea and vomiting: Change at C8 D1 (n=17, 21) | -4.9 ± 18.41 | 0.8 ± 22.66 |
| Nausea and vomiting: Change at C9 D1 (n=9, 9) | -13.0 ± 32.02 | -5.6 ± 18.64 |
| Nausea and vomiting: Change at C10 D1 (n=3, 4) | -11.1 ± 19.23 | 8.3 ± 9.58 |
| Nausea and vomiting: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Nausea and vomiting: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Nausea and vomiting: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Nausea and vomiting: Change at followup (n=68, 73) | 9.8 ± 25.63 | 7.5 ± 22.40 |
| Pain: Baseline (n=291, 291) | 40.7 ± 30.16 | 36.9 ± 29.57 |
| Pain: Change at C2 D1 (n=231, 234) | -10.1 ± 29.47 | -7.9 ± 25.28 |
| Pain: Change at C3 D1 (n=169, 181) | -13.6 ± 29.81 | -11.2 ± 26.63 |
| Pain: Change at C4 D1 (n=131, 135) | -12.2 ± 32.48 | -7.8 ± 27.14 |
| Pain: Change at C5 D1 (n=97, 80) | -10.5 ± 32.75 | -6.9 ± 26.21 |
| Pain: Change at C6 D1 (n=59, 58) | -11.9 ± 27.51 | -7.5 ± 29.48 |
| Pain: Change at C7 D1 (n=38, 35) | -14.0 ± 27.81 | -9.5 ± 24.67 |
| Pain: Change at C8 D1 (n=17, 20) | -9.8 ± 26.39 | -6.7 ± 29.32 |
| Pain: Change at C9 D1 (n=9, 9) | -22.2 ± 43.29 | -5.6 ± 39.08 |
| Pain: Change at C10 D1 (n=3, 4) | -33.3 ± 33.30 | -4.2 ± 45.88 |
| Pain: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -33.3 ± NA |
| Pain: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pain: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pain: Change at follow-up (n=66, 72) | 3.3 ± 37.01 | 3.5 ± 31.14 |
| Dyspnoea: Baseline (n=295, 295) | 16.1 ± 22.30 | 14.8 ± 23.55 |
| Dyspnoea: Change at C2 D1 (n=238, 240) | 5.5 ± 23.58 | 2.1 ± 20.91 |
| Dyspnoea: Change at C3 D1 (n=175, 186) | 5.7 ± 26.84 | 3.9 ± 24.67 |
| Dyspnoea: Change at C4 D1 (n=135, 135) | 7.7 ± 26.99 | 4.4 ± 21.08 |
| Dyspnoea: Change at C5 D1 (n=98, 82) | 4.4 ± 26.05 | 2.8 ± 18.29 |
| Dyspnoea: Change at C6 D1 (n=60, 59) | 9.4 ± 26.09 | -0.0 ± 16.37 |
| Dyspnoea: Change at C7 D1 (n=37, 37) | 6.3 ± 24.63 | 5.4 ± 20.05 |
| Dyspnoea: Change at C8 D1 (n=16, 21) | 4.2 ± 20.62 | 12.7 ± 24.66 |
| Dyspnoea: Change at C9 D1 (n=9, 9) | 11.1 ± 47.14 | 14.8 ± 29.39 |
| Dyspnoea: Change at C10 D1 (n=3, 4) | -11.1 ± 50.92 | 0.0 ± 27.19 |
| Dyspnoea: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Dyspnoea: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Dyspnoea: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Dyspnoea: Change at follow-up (n=68, 73) | 13.2 ± 28.30 | 8.7 ± 24.23 |
| Insomnia: Baseline (n=297, 295) | 36.8 ± 31.95 | 32.2 ± 32.17 |
| Insomnia: Change at C2 D1 (n=240, 241) | -13.6 ± 33.55 | -7.3 ± 33.16 |
| Insomnia: Change at C3 D1 (n=178, 185) | -13.5 ± 33.33 | -8.7 ± 33.30 |
| Insomnia: Change at C4 D1 (n=134, 134) | -12.7 ± 38.52 | -11.2 ± 27.41 |
| Insomnia: Change at C5 D1 (n=99, 82) | -14.5 ± 33.05 | -7.3 ± 28.70 |
| Insomnia: Change at C6 D1 (n=60, 59) | -8.3 ± 30.46 | -2.3 ± 30.86 |
| Insomnia: Change at C7 D1 (n=37, 37) | -11.7 ± 36.19 | -2.7 ± 19.84 |
| Insomnia: Change at C8 D1 (n=17, 21) | 5.9 ± 35.82 | -3.2 ± 20.82 |
| Insomnia: Change at C9 D1 (n=9, 9) | -14.8 ± 24.23 | -0.0 ± 23.56 |
| Insomnia: Change at C10 D1 (n=3, 4) | 11.1 ± 19.23 | -0.0 ± 27.23 |
| Insomnia: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 33.3 ± NA |
| Insomnia: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Insomnia: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Insomnia: Change at follow-up (n=68, 73) | 1.5 ± 36.63 | 1.4 ± 28.02 |
| Loss of appetite: Baseline (n=297, 295) | 39.6 ± 35.49 | 37.5 ± 33.36 |
| Loss of appetite: Change at C2 D1 (n=240, 240) | -2.1 ± 34.24 | -2.6 ± 27.91 |
| Loss of appetite: Change at C3 D1 (n=178, 186) | -1.3 ± 31.57 | -5.9 ± 31.50 |
| Loss of appetite: Change at C4 D1 (n=135, 135) | 0.0 ± 35.27 | -6.7 ± 29.88 |
| Loss of appetite: Change at C5 D1 (n=99, 82) | 1.7 ± 35.76 | -4.5 ± 30.44 |
| Loss of appetite: Change at C6 D1 (n=60, 59) | 2.8 ± 33.22 | -4.5 ± 29.34 |
| Loss of appetite: Change at C7 D1 (n=38, 37) | 0.9 ± 35.92 | -7.2 ± 27.37 |
| Loss of appetite: Change at C8 D1 (n=17, 20) | 7.8 ± 25.07 | -1.7 ± 29.57 |
| Loss of appetite: Change at C9 D1 (n=9, 9) | -14.8 ± 29.41 | -7.4 ± 36.44 |
| Loss of appetite: Change at C10 D1 (n=3, 4) | -22.2 ± 19.23 | 0.0 ± 38.48 |
| Loss of appetite: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 33.3 ± NA |
| Loss of appetite: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Loss of appetite: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Loss of appetite: Change at follow-up (n=67, 73) | 7.0 ± 39.17 | 7.8 ± 36.24 |
| Constipation: Baseline (n=293, 289) | 30.7 ± 32.13 | 29.6 ± 32.66 |
| Constipation: Change at C2 D1 (n=234, 235) | -4.8 ± 32.18 | -2.8 ± 33.21 |
| Constipation: Change at C3 D1 (n =173, 181) | -7.3 ± 32.12 | -6.1 ± 36.43 |
| Constipation: Change at C4 D1 (n=134, 135) | -6.5 ± 35.99 | -10.6 ± 36.80 |
| Constipation: Change at C5 D1 (n=97, 80) | -11.0 ± 33.59 | -8.7 ± 29.88 |
| Constipation: Change at C6 D1 (n=60, 58) | -5.6 ± 37.42 | -9.8 ± 32.45 |
| Constipation: Change at C7 D1 (n=38, 36) | -2.6 ± 31.37 | -13.0 ± 32.15 |
| Constipation: Change at C8 D1 (n=17, 20) | 0.0 ± 28.87 | -16.7 ± 39.74 |
| Constipation: Change at C9 D1 (n=9, 9) | -18.5 ± 33.79 | -29.6 ± 35.14 |
| Constipation: Change at C10 D1 (n=3, 4) | -11.1 ± 19.23 | -50.0 ± 43.04 |
| Constipation: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -66.7 ± NA |
| Constipation: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Constipation: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Constipation: Change at follow-up (n=66, 71) | 5.1 ± 42.27 | -6.1 ± 35.77 |
| Diarrhoea: Baseline (n=294, 290) | 14.3 ± 21.68 | 13.7 ± 24.19 |
| Diarrhoea: Change at C2 D1 (n=235, 235) | 1.7 ± 25.73 | 0.3 ± 21.78 |
| Diarrhoea: Change at C3 D1 (n=173, 182) | 9.4 ± 28.66 | 0.2 ± 23.10 |
| Diarrhoea: Change at C4 D1 (n=134, 136) | 7.7 ± 28.00 | -1.5 ± 22.53 |
| Diarrhoea: Change at C5 D1 (n=96, 81) | 11.8 ± 27.35 | 1.2 ± 27.10 |
| Diarrhoea: Change at C6 D1 (n=60, 58) | 20.0 ± 33.72 | 1.7 ± 28.22 |
| Diarrhoea: Change at C7 D1 (n=38, 36) | 14.9 ± 32.60 | 2.8 ± 23.05 |
| Diarrhoea: Change at C8 D1 (n=17, 20) | 25.5 ± 38.24 | 1.7 ± 27.52 |
| Diarrhoea: Change at C9 D1 (n=9, 9) | 37.0 ± 45.47 | 22.2 ± 33.35 |
| Diarrhoea: Change at C10 D1 (n=3, 4) | 22.2 ± 50.91 | 16.7 ± 19.23 |
| Diarrhoea: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Diarrhoea: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Diarrhoea: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Diarrhoea: Change at follow-up (n=66, 71) | 2.5 ± 29.41 | 2.8 ± 25.03 |
| Financial difficulties (FD): Baseline (n=292, 285) | 24.7 ± 30.41 | 23.0 ± 30.83 |
| FD:Change at C2 D1 (n=233, 228) | -3.1 ± 22.95 | -4.5 ± 23.29 |
| FD: Change at C3 D1 (n=171, 176) | -7.2 ± 26.94 | -3.4 ± 23.39 |
| FD: Change at C4 D1 (n=133, 133) | -5.5 ± 26.33 | -3.3 ± 23.52 |
| FD: Change at C5 D1 (n=96, 80) | -4.9 ± 21.62 | 1.3 ± 25.68 |
| FD: Change at C6 D1 (n=60, 56) | -3.9 ± 24.61 | -1.8 ± 28.02 |
| FD: Change at C7 D1 (n=37, 34) | -2.7 ± 24.06 | -3.9 ± 32.60 |
| FD: Change at C8 D1 (n=17, 17) | 2.0 ± 14.28 | 2.0 ± 34.31 |
| FD: Change at C9 D1 (n=9, 9) | 7.4 ± 22.23 | 3.7 ± 45.49 |
| FD: Change at C10 D1 (n=3, 4) | 0.0 ± 0.00 | 25.0 ± 41.94 |
| FD: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 66.7 ± NA |
| FD: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| FD: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| FD: Change at follow-up (n=65, 70) | 6.7 ± 29.59 | -0.5 ± 21.61 |
| GHS/Quality of Life (QoL): Baseline (n=292, 288) | 54.2 ± 22.34 | 57.1 ± 23.14 |
| GHS/QoL:Change at C2 D1 (n=234, 233) | 2.2 ± 23.36 | 1.9 ± 22.39 |
| GHS/QoL:Change at C3 D1 (n=168, 180) | -0.3 ± 25.42 | 5.7 ± 21.45 |
| GHS/QoL:Change at C4 D1(n=132, 132) | 0.1 ± 23.79 | 2.8 ± 21.54 |
| GHS/QoL:Change at C5 D1 (n=96, 81) | 1.5 ± 22.63 | 2.7 ± 18.35 |
| GHS/QoL:Change at C6 D1 (n=60, 57) | 0.8 ± 21.41 | 3.2 ± 23.40 |
| GHS/QoL:Change at C7 D1 (n=38, 35) | 2.6 ± 23.01 | 2.1 ± 22.35 |
| GHS/QoL:Change at C8 D1 (n=17, 19) | -1.0 ± 23.73 | 1.3 ± 23.76 |
| GHS/QoL:Change at C9 D1 (n=9, 9) | 7.4 ± 16.89 | -8.3 ± 20.39 |
| GHS/QoL: Change at C10 D1 (n=3, 4) | 22.3 ± 19.28 | -0.0 ± 32.59 |
| GHS/QoL: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| GHS/QoL: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| GHS/QoL: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| GHS/QoL:Change at follow-up (n=65, 71) | -9.1 ± 26.06 | -6.7 ± 24.50 |
QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.
| Units on a scale | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Pancreatic Pain: Baseline (n=246, 250) | 41.6 ± 27.16 | 40.0 ± 25.54 |
| Pancreatic Pain: Change at C2 D1 (n=191, 197) | -10.9 ± 24.38 | -10.1 ± 22.93 |
| Pancreatic Pain: Change at C3 D1 (n=141, 153) | -16.3 ± 25.51 | -11.2 ± 24.92 |
| Pancreatic Pain: Change at C4 D1 (n=99, 111) | -13.2 ± 28.70 | -11.4 ± 26.16 |
| Pancreatic Pain: Change at C5 D1 (n=67, 64) | -15.8 ± 28.06 | -13.0 ± 23.85 |
| Pancreatic Pain: Change at C6 D1 (n=41, 43) | -15.9 ± 25.47 | -13.0 ± 24.62 |
| Pancreatic Pain: Change at C7 D1 (n=25, 25) | -15.3 ± 28.02 | -15.0 ± 25.69 |
| Pancreatic Pain: Change at C8 D1 (n=11, 11) | -7.6 ± 27.76 | -9.8 ± 30.01 |
| Pancreatic Pain: Change at C9 D1 (n=6, 6) | -29.2 ± 31.06 | 0.0 ± 15.81 |
| Pancreatic Pain: Change at C10 D1 (n=2, 3) | -20.9 ± 29.49 | 5.6 ± 26.79 |
| Pancreatic Pain: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Pancreatic Pain: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pancreatic Pain: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pancreatic Pain: Change at follow-up (n=47, 46) | -3.5 ± 29.59 | -3.6 ± 28.80 |
| Hepatic: Baseline (n=245, 254) | 10.2 ± 17.21 | 10.8 ± 17.59 |
| Hepatic: Change at C2 D1 (n=193, 205) | 0.3 ± 18.24 | -2.0 ± 17.67 |
| Hepatic: Change at C3 D1 (n=142, 157) | -1.4 ± 16.78 | -2.5 ± 18.60 |
| Hepatic: Change at C4 D1 (n=99, 112) | -2.5 ± 18.34 | -2.4 ± 18.15 |
| Hepatic: Change at C5 D1 (n=68, 64) | 1.0 ± 17.49 | -2.6 ± 16.60 |
| Hepatic: Change at C6 D1 (n=40, 41) | 0.4 ± 15.34 | -3.2 ± 17.57 |
| Hepatic: Change at C7 D1 (n=25, 24) | -0.7 ± 16.30 | -4.9 ± 18.70 |
| Hepatic: Change at C8 D1 (n=11, 12) | -4.5 ± 13.10 | -4.2 ± 12.57 |
| Hepatic: Change at C9 D1 (n=6, 5) | -11.1 ± 13.60 | -13.3 ± 13.94 |
| Hepatic: Change at C10 D1 (n=2, 2) | -16.7 ± 23.55 | -8.4 ± 11.81 |
| Hepatic: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Hepatic: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Hepatic: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Hepatic: Change at follow-up (n=47, 48) | 2.8 ± 23.38 | -1.4 ± 23.27 |
| Digestive Symptom: Baseline (n=250, 255) | 34.3 ± 30.78 | 33.9 ± 31.05 |
| Digestive Symptom: Change at C2 D1 (n=195, 206) | 2.8 ± 29.15 | 0.6 ± 26.72 |
| Digestive Symptom: Change at C3 D1 (n=144, 159) | -1.2 ± 31.58 | -4.3 ± 32.97 |
| Digestive Symptom: Change at C4 D1 (n=100, 114) | 0.5 ± 30.57 | -4.5 ± 30.90 |
| Digestive Symptom: Change at C5 D1 (n=69, 65) | 1.4 ± 32.80 | -3.6 ± 36.14 |
| Digestive Symptom: Change at C6 D1 (n=40, 45) | 3.3 ± 30.23 | 0.4 ± 35.97 |
| Digestive Symptom: Change at C7 D1 (n=25, 26) | -6.0 ± 30.76 | -1.3 ± 24.91 |
| Digestive Symptom: Change at C8 D1 (n=11, 14) | 4.5 ± 42.87 | 17.9 ± 23.07 |
| Digestive Symptom: Change at C9 D1 (n=6, 6) | -13.9 ± 46.44 | 22.2 ± 25.10 |
| Digestive Symptom: Change at C10 D1 (n=2, 3) | -33.3 ± 47.09 | 11.1 ± 19.23 |
| Digestive Symptom: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 66.7 ± NA |
| Digestive Symptom: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Digestive Symptom: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Digestive Symptom: Change at follow-up (n=47, 47) | 6.0 ± 38.14 | 2.8 ± 35.83 |
| Sexuality: Baseline (n=217, 232) | 56.8 ± 36.90 | 55.5 ± 38.04 |
| Sexuality: Change at C2 D1 (n=157, 181) | -0.5 ± 37.81 | -4.0 ± 33.17 |
| Sexuality: Change at C3 D1 (n=118, 139) | -4.9 ± 37.70 | -3.0 ± 32.25 |
| Sexuality: Change at C4 D1 (n=85, 100) | -4.1 ± 38.40 | 3.0 ± 29.90 |
| Sexuality: Change at C5 D1 (n=55, 58) | -1.5 ± 34.30 | -5.2 ± 29.32 |
| Sexuality: Change at C6 D1 (n=30, 38) | 12.2 ± 29.67 | -11.4 ± 33.58 |
| Sexuality: Change at C7 D1 (n=19, 21) | 4.4 ± 35.06 | -7.1 ± 31.88 |
| Sexuality: Change at C8 D1 (n=8, 10) | 12.5 ± 24.82 | -15.0 ± 26.59 |
| Sexuality: Change at C9 D1 (n=4, 6) | 25.0 ± 31.93 | 0.0 ± 23.55 |
| Sexuality: Change at C10 D1 (n=0, 3) | NA ± NA | 11.1 ± 19.28 |
| Sexuality: Change at C11 D1 (n=0, 1) | NA ± NA | 33.3 ± NA |
| Sexuality: Change at C12 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Sexuality: Change at C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Sexuality: Change at follow-up (n=36, 41) | -3.2 ± 41.18 | -23.2 ± 42.31 |
| Health care(HC)satisfaction: Baseline (n=241, 247) | 78.0 ± 26.66 | 78.3 ± 23.94 |
| HC satisfaction: Change at C2 D1 (n=182, 194) | 0.1 ± 27.73 | 1.8 ± 24.13 |
| HC satisfaction: Change at C3 D1 (n=135, 149) | 0.2 ± 31.54 | 5.4 ± 24.98 |
| HC satisfaction: Change at C4 D1 (n=97, 108) | -4.3 ± 34.88 | -0.2 ± 26.52 |
| HC satisfaction: Change at C5 D1 (n=66, 59) | 1.0 ± 29.66 | 0.8 ± 28.77 |
| HC satisfaction: Change at C6 D1 (n=40, 39) | -6.7 ± 26.91 | -0.4 ± 27.96 |
| HC satisfaction: Change at C7 D1 (n=27, 20) | -4.3 ± 22.44 | 6.7 ± 33.06 |
| HC satisfaction: Change at C8 D1 (n=12, 11) | -16.7 ± 52.23 | 7.6 ± 20.22 |
| HC satisfaction: Change at C9 D1 (n=6, 6) | 16.7 ± 47.14 | -5.6 ± 17.23 |
| HC satisfaction: Change at C10 D1 (n=2, 3) | -33.3 ± 0.0 | 5.6 ± 9.64 |
| HC satisfaction: Change at C11 D1 (n=1, 1) | -33.3 ± NA | 0.0 ± NA |
| HC satisfaction: Change at C12 D1 (n=1, 0) | -33.3 ± NA | NA ± NA |
| HC satisfaction: Change at C13 D1(n=1, 0) | -33.3 ± NA | NA ± NA |
| HC satisfaction: Change at follow-up (n=46, 45) | -0.7 ± 29.39 | -2.2 ± 31.50 |
| Body Image: Baseline (n=249, 251) | 28.5 ± 28.46 | 28.8 ± 28.67 |
| Body Image: Change at C2 D1 (n=189, 200) | 4.9 ± 23.11 | -0.2 ± 26.78 |
| Body Image: Change at C3 D1 (n=142, 149) | 4.9 ± 22.26 | 2.1 ± 26.16 |
| Body Image: Change at C4 D1 (n=97, 111) | 6.7 ± 26.20 | 0.9 ± 26.48 |
| Body Image: Change at C5 D1 (n=70, 62) | 4.8 ± 26.33 | -0.3 ± 25.87 |
| Body Image: Change at C6 D1 (n=40, 42) | 8.3 ± 28.24 | -0.8 ± 33.92 |
| Body Image: Change at C7 D1 (n=25, 24) | 12.0 ± 27.43 | -5.6 ± 33.22 |
| Body Image: Change at C8 D1 (n=11, 12) | 21.2 ± 42.23 | 11.1 ± 32.04 |
| Body Image: Change at C9 D1 (n=6, 6) | 33.3 ± 52.69 | 8.3 ± 46.87 |
| Body Image: Change at C10 D1 (n=2, 3) | -8.3 ± 11.74 | 5.6 ± 78.77 |
| Body Image: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -50.0 ± NA |
| Body Image: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Body Image: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Body Image: Change at follow-up (n=47, 45) | 13.1 ± 30.67 | 11.5 ± 24.56 |
| Altered Bowel Habit: Baseline (n=250, 255) | 20.3 ± 22.92 | 21.2 ± 25.72 |
| Altered Bowel Habit: Change at C2 D1 (n=193, 204) | 3.0 ± 24.19 | 1.5 ± 22.21 |
| Altered Bowel Habit: Change at C3 D1 (n=143, 156) | 6.2 ± 26.37 | 2.5 ± 24.67 |
| Altered Bowel Habit: Change at C4 D1 (n=98, 114) | 6.6 ± 25.52 | 4.8 ± 22.14 |
| Altered Bowel Habit: Change at C5 D1 (n=68, 63) | 8.3 ± 33.15 | 1.3 ± 24.56 |
| Altered Bowel Habit: Change at C6 D1 (n=40, 43) | 9.6 ± 30.63 | 2.3 ± 28.07 |
| Altered Bowel Habit: Change at C7 D1 (n=25, 25) | 6.0 ± 25.40 | 1.3 ± 30.77 |
| Altered Bowel Habit: Change at C8 D1 (n=11, 13) | 1.5 ± 29.29 | 7.7 ± 38.86 |
| Altered Bowel Habit: Change at C9 D1 (n=6, 6) | 13.9 ± 32.35 | -5.6 ± 51.27 |
| Altered Bowel Habit: Change at C10 D1 (n=2, 3) | -8.3 ± 35.36 | -16.7 ± 72.62 |
| Altered Bowel Habit: Change at C11 D1 (n=1, 1) | 16.7 ± NA | -100.0 ± NA |
| Altered Bowel Habit: Change at C12 D1 (n=1, 0) | 16.7 ± NA | NA ± NA |
| Altered Bowel Habit: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Altered Bowel Habit: Change at followup (n=47, 48) | 6.0 ± 29.36 | 5.9 ± 21.33 |
| Ascites: Baseline (n=250, 256) | 38.7 ± 32.98 | 32.9 ± 30.61 |
| Ascites: Change at C2 D1 (n=197, 207) | -8.6 ± 33.32 | -3.4 ± 29.65 |
| Ascites: Change at C3 D1 (n=144, 158) | -8.3 ± 33.34 | -5.1 ± 28.70 |
| Ascites: Change at C4 D1 (n=101, 114) | -5.0 ± 36.64 | -0.3 ± 26.05 |
| Ascites: Change at C5 D1 (n=71, 65) | -8.5 ± 34.15 | -0.5 ± 29.17 |
| Ascites: Change at C6 D1 (n=42, 45) | -3.2 ± 31.08 | -2.2 ± 32.10 |
| Ascites: Change at C7 D1 (n=26, 26) | -14.1 ± 32.91 | -12.8 ± 23.25 |
| Ascites: Change at C8 D1 (n=11, 14) | -18.2 ± 43.12 | -11.9 ± 28.05 |
| Ascites: Change at C9 D1 (n=6, 6) | -11.1 ± 34.42 | -16.7 ± 34.95 |
| Ascites: Change at C10 D1 (n=2, 3) | -16.7 ± 23.55 | 22.2 ± 38.51 |
| Ascites: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 33.3 ± NA |
| Ascites: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Ascites: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Ascites: Change at follow-up (n=48, 48) | 5.6 ± 35.96 | -2.1 ± 26.11 |
| Indigestion: Baseline (n=252, 257) | 29.4 ± 30.38 | 24.0 ± 28.55 |
| Indigestion: Change at C2 D1 (n=198, 208) | -0.3 ± 26.87 | -2.4 ± 24.29 |
| Indigestion: Change at C3 D1 (n=144, 159) | 0.2 ± 30.16 | -5.2 ± 25.59 |
| Indigestion: Change at C4 D1 (n=101, 115) | -4.0 ± 24.63 | -4.1 ± 25.80 |
| Indigestion: Change at C5 D1 (n=71, 65) | 0.5 ± 29.01 | -4.6 ± 22.72 |
| Indigestion: Change at C6 D1 (n=41, 45) | 1.6 ± 31.58 | -1.5 ± 24.57 |
| Indigestion: Change at C7 D1 (n=26, 26) | -3.8 ± 19.60 | -1.3 ± 17.59 |
| Indigestion: Change at C8 D1 (n=11, 14) | 0.0 ± 21.06 | 2.4 ± 20.53 |
| Indigestion: Change at C9 D1 (n=6, 6) | -5.6 ± 25.07 | 11.1 ± 27.23 |
| Indigestion: Change at C10 D1 (n=2, 3) | -16.7 ± 23.55 | 22.2 ± 19.23 |
| Indigestion: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Indigestion: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Indigestion: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Indigestion: Change at follow-up (n=48, 48) | 7.6 ± 30.94 | 1.4 ± 30.73 |
| Flatulence: Baseline (n=249, 256) | 37.9 ± 32.34 | 34.0 ± 31.31 |
| Flatulence: Change at C2 D1 (n=197, 206) | 1.2 ± 29.81 | 2.6 ± 31.82 |
| Flatulence: Change at C3 D1 (n=146, 159) | 3.2 ± 33.07 | 0.2 ± 34.48 |
| Flatulence: Change at C4 D1 (n=101, 115) | -1.3 ± 33.65 | 2.3 ± 32.07 |
| Flatulence: Change at C5 D1 (n=70, 65) | -1.0 ± 32.60 | 1.0 ± 31.17 |
| Flatulence: Change at C6 D1 (n=41, 45) | -1.6 ± 26.83 | -1.5 ± 29.27 |
| Flatulence: Change at C7 D1 (n=25, 26) | -1.3 ± 26.31 | -3.8 ± 23.71 |
| Flatulence: Change at C8 D1 (n=10, 14) | -10.0 ± 35.34 | 2.4 ± 27.62 |
| Flatulence: Change at C9 D1 (n=5, 6) | 0.0 ± 0.00 | 5.6 ± 13.59 |
| Flatulence: Change at C10 D1 (n=1, 3) | 33.3 ± NA | -11.1 ± 19.23 |
| Flatulence: Change at C11 D1 (n=0, 1) | NA ± NA | 0.0 ± NA |
| Flatulence: Change at C12 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Flatulence: Change at C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Flatulence: Change at follow-up (n=48, 46) | -0.7 ± 35.41 | 2.2 ± 34.00 |
| Cachexia: Baseline (n=251, 253) | 33.1 ± 27.62 | 33.6 ± 26.84 |
| Cachexia: Change at C2 D1 (n=197, 205) | 4.2 ± 24.26 | 0.6 ± 21.63 |
| Cachexia: Change at C3 D1 (n=145, 157) | 4.6 ± 25.87 | -3.3 ± 21.13 |
| Cachexia: Change at C4 D1 (n=101, 112) | 1.2 ± 26.37 | -6.2 ± 24.82 |
| Cachexia: Change at C5 D1 (n=70, 64) | 0.5 ± 28.37 | -8.3 ± 24.48 |
| Cachexia: Change at C6 D1 (n=40, 44) | -2.1 ± 24.80 | -5.3 ± 24.84 |
| Cachexia: Change at C7 D1 (n=24, 26) | -0.7 ± 24.31 | -5.1 ± 25.27 |
| Cachexia: Change at C8 D1 (n=10, 14) | 15.0 ± 34.64 | -4.7 ± 21.12 |
| Cachexia: Change at C9 D1 (n=5, 6) | 16.7 ± 31.16 | 2.8 ± 19.47 |
| Cachexia: Change at C10 D1 (n=1, 3) | 0.0 ± NA | 0.0 ± 28.87 |
| Cachexia: Change at C11 D1 (n=0, 1) | NA ± NA | -16.6 ± NA |
| Cachexia: Change at C12 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Cachexia: Change at C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Cachexia: Change at follow-up (n=48, 47) | 8.0 ± 31.69 | 6.4 ± 30.79 |
| Side Effects: Baseline (n=209, 226) | 24.9 ± 21.21 | 27.4 ± 23.08 |
| Side Effects: Change at C2 D1 (n=159, 181) | 11.2 ± 23.11 | 5.8 ± 22.06 |
| Side Effects: Change at C3 D1 (n=113, 137) | 13.0 ± 24.67 | 4.7 ± 22.18 |
| Side Effects: Change at C4 D1 (n=80, 102) | 10.1 ± 20.64 | 4.9 ± 22.48 |
| Side Effects: Change at C5 D1 (n=54, 59) | 7.4 ± 25.55 | 3.6 ± 23.84 |
| Side Effects: Change at C6 D1 (n=29, 40) | 8.1 ± 26.72 | -1.4 ± 25.32 |
| Side Effects: Change at C7 D1 (n=17, 22) | 15.0 ± 20.77 | -1.0 ± 19.38 |
| Side Effects: Change at C8 D1 (n=8, 11) | 9.7 ± 19.19 | -3.0 ± 22.83 |
| Side Effects: Change at C9 D1 (n=3, 6) | 14.8 ± 23.15 | -1.9 ± 27.60 |
| Side Effects: Change at C10 D1 (n=0, 3) | NA ± NA | 0.0 ± 40.12 |
| Side Effects: Change at C11 D1 (n=0, 1) | NA ± NA | -33.4 ± NA |
| Side Effects: Change at C12 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Side Effects: Change at C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Side Effects: Change at follow-up (n=42, 42) | 18.8 ± 24.37 | 13.2 ± 27.80 |
| Fear of Future Health (FH): Baseline (n=252, 250)) | 59.3 ± 31.33 | 61.1 ± 33.07 |
| Fear of FH: Change at C2 D1 (n=192, 201) | -3.5 ± 31.82 | -9.6 ± 28.80 |
| Fear of FH: Change at C3 D1 (n=145, 155) | -0.9 ± 34.02 | -11.6 ± 30.07 |
| Fear of FH: Change at C4 D1 (n=103, 113) | -4.5 ± 32.70 | -15.9 ± 30.90 |
| Fear of FH: Change at C5 D1 (n=71, 64) | -0.5 ± 31.12 | -10.9 ± 29.74 |
| Fear of FH: Change at C6 D1 (n=42, 44) | -4.8 ± 30.86 | -14.4 ± 32.47 |
| Fear of FH: Change at C7 D1 (n=27, 25) | -6.2 ± 22.72 | -13.3 ± 33.34 |
| Fear of FH: Change at C8 D1 (n=12, 12) | 2.8 ± 30.02 | 5.6 ± 27.84 |
| Fear of FH: Change at C9 D1 (n=6, 6) | 16.7 ± 27.90 | 16.7 ± 34.96 |
| Fear of FH: Change at C10 D1 (n=2, 3) | -16.7 ± 23.62 | 11.1 ± 50.96 |
| Fear of FH: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Fear of FH: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Fear of FH: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Fear of FH:Change at follow-up (n=48, 45) | 5.6 ± 28.63 | -4.4 ± 38.67 |
| Future Plan ability: Baseline (n=250, 249) | 34.3 ± 33.59 | 38.0 ± 34.40 |
| Future Plan ability: Change at C2 D1 (n=192, 198) | 6.1 ± 38.19 | -0.3 ± 34.58 |
| Future Plan ability:Change at C3 D1 (n=142, 153) | 3.5 ± 39.65 | 0.4 ± 36.68 |
| Future Plan ability:Change at C4 D1 (n=101, 112) | 5.6 ± 36.55 | 0.3 ± 37.04 |
| Future Plan ability:Change at C5 D1 (n=70, 62) | 0.9 ± 34.05 | -3.8 ± 39.17 |
| Future Plan ability:Change at C6 D1 (n=42, 42) | 4.8 ± 34.99 | 0.8 ± 46.27 |
| Future Plan ability: Change at C7 D1 (n=26, 24) | 2.6 ± 28.18 | -7.0 ± 36.76 |
| Future Plan ability: Change at C8 D1 (n=11, 11) | 6.1 ± 32.74 | 3.0 ± 43.36 |
| Future Plan ability: Change at C9 D1 (n=5, 6) | 0.0 ± 23.55 | 0.0 ± 55.78 |
| Future Plan ability: Change at C10 D1 (n=1, 3) | 0.0 ± NA | -11.1 ± 69.43 |
| Future Plan ability: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -66.7 ± NA |
| Future Plan ability: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Future Plan ability: Change at C13 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Future Plan ability: Change at followup (n=48, 45) | 21.5 ± 35.40 | 5.2 ± 38.25 |
BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
| Units on a scale | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Worst Pain: Baseline (n=247, 250) | 3.8 ± 2.84 | 3.7 ± 2.96 |
| Worst Pain: Change at C2 D1 (n=192, 200) | -0.7 ± 3.04 | -0.9 ± 2.84 |
| Worst Pain: Change at C3 D1 (n=138, 151) | -1.5 ± 3.09 | -0.9 ± 2.83 |
| Worst Pain: Change at C4 D1 (n=99, 113) | -1.0 ± 3.41 | -0.9 ± 3.09 |
| Worst Pain: Change at C5 D1 (n=69, 64) | -1.1 ± 3.43 | -1.2 ± 3.08 |
| Worst Pain: Change at C6 D1 (n=41, 43) | -0.9 ± 2.98 | -1.0 ± 3.17 |
| Worst Pain: Change at C7 D1 (n=25, 26) | -0.8 ± 2.27 | -0.9 ± 3.50 |
| Worst Pain: Change at C8 D1 (n=12, 13) | 0.8 ± 2.56 | -1.5 ± 3.20 |
| Worst Pain: Change at C9 D1(n=6, 6) | -1.8 ± 1.94 | -1.3 ± 1.51 |
| Worst Pain: Change at C10 D1 (n=2, 3) | -2.0 ± 2.83 | -0.3 ± 2.31 |
| Worst Pain: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Worst Pain: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Worst Pain: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -4.0 ± NA |
| Worst Pain: Change at follow-up (n=47, 46) | 0.5 ± 3.08 | 0.0 ± 3.21 |
| Pain in Last 24 Hours (hrs): Baseline (n=246, 248) | 1.8 ± 1.92 | 1.7 ± 1.93 |
| Pain in Last 24 hrs: Change at C2 D1 (n=193, 197) | -0.2 ± 2.21 | -0.3 ± 1.92 |
| Pain in Last 24 hrs: Change at C3 D1 (n=138, 150) | -0.6 ± 2.01 | -0.3 ± 1.88 |
| Pain in Last 24 hrs: Change at C4 D1 (n=99, 112) | -0.3 ± 2.15 | -0.0 ± 1.96 |
| Pain in Last 24 hrs: Change at C5 D1 (n=69, 63) | -0.3 ± 2.41 | -0.2 ± 2.04 |
| Pain in Last 24 hrs: Change at C6 D1 (n=40, 43) | -0.2 ± 2.07 | -0.1 ± 1.64 |
| Pain in Last 24 hrs: Change at C7 D1 (n=25, 26) | 0.4 ± 1.47 | -0.0 ± 2.46 |
| Pain in Last 24 hrs: Change at C8 D1 (n=12, 13) | 1.3 ± 2.34 | -0.2 ± 1.41 |
| Pain in Last 24 hrs: Change at C9 D1 (n=6, 6) | -0.3 ± 1.37 | 0.2 ± 1.60 |
| Pain in Last 24 hrs: Change at C10 D1 (n=2, 3) | -1.5 ± 2.12 | 0.3 ± 0.58 |
| Pain in Last 24 hrs: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 4.0 ± NA |
| Pain in Last 24 hrs: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pain in Last 24 hrs: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -1.0 ± NA |
| Pain in Last 24 hrs: Change at followup (n=48, 45) | 0.4 ± 2.70 | 0.8 ± 2.58 |
| Pain on the Average: Baseline (n=246, 248) | 2.9 ± 2.16 | 2.8 ± 2.27 |
| Pain on the Average: Change at C2 D1 (n=195, 198) | -0.5 ± 2.02 | -0.5 ± 2.29 |
| Pain on the Average: Change at C3 D1 (n=140, 149) | -0.8 ± 2.48 | -0.5 ± 2.10 |
| Pain on the Average: Change at C4 D1 (n=99, 113) | -0.7 ± 2.44 | -0.6 ± 2.03 |
| Pain on the Average: Change at C5 D1 (n=69, 63) | -0.7 ± 2.48 | -0.6 ± 2.29 |
| Pain on the Average: Change at C6 D1 (n=40, 43) | -0.5 ± 2.07 | -0.9 ± 2.12 |
| Pain on the Average: Change at C7 D1 (n=25, 26) | -0.3 ± 1.46 | -0.5 ± 2.97 |
| Pain on the Average: Change at C8 D1 (n=12, 13) | 1.0 ± 2.00 | -1.4 ± 1.94 |
| Pain on the Average: Change at C9 D1 (n=6, 6) | -1.7 ± 1.51 | -1.7 ± 1.86 |
| Pain on the Average: Change at C10 D1 (n=2, 3) | -2.0 ± 2.83 | -1.0 ± 2.65 |
| Pain on the Average: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -3.0 ± NA |
| Pain on the Average: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pain on the Average: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -2.0 ± NA |
| Pain on the Average: Change at followup (n=48, 45) | 0.6 ± 2.70 | 0.4 ± 2.74 |
| Pain Right Now: Baseline (n=248, 249) | 2.1 ± 2.13 | 2.1 ± 2.36 |
| Pain Right Now: Change at C2 D1 (n=196, 200) | -0.4 ± 2.23 | -0.5 ± 2.37 |
| Pain Right Now: Change at C3 D1 (n=140, 150) | -0.8 ± 2.31 | -0.6 ± 2.06 |
| Pain Right Now: Change at C4 D1 (n=99, 113) | -0.6 ± 2.26 | -0.5 ± 2.45 |
| Pain Right Now: Change at C5 D1 (n=68, 63) | -0.5 ± 2.76 | -0.3 ± 2.65 |
| Pain Right Now: Change at C6 D1 (n=40, 43) | -0.5 ± 1.96 | -0.5 ± 2.14 |
| Pain Right Now: Change at C7 D1 (n=25, 26) | 0.1 ± 1.66 | -0.2 ± 3.26 |
| Pain Right Now: Change at C8 D1 (n=12, 13) | 1.1 ± 1.93 | -0.6 ± 1.56 |
| Pain Right Now: Change at C9 D1 (n=6, 6) | -1.5 ± 1.76 | -0.3 ± 0.52 |
| Pain Right Now: Change at C10 D1 (n=2, 3) | -2.0 ± 2.83 | 0.7 ± 1.15 |
| Pain Right Now: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 5.0 ± NA |
| Pain Right Now: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Pain Right Now: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -5.0 ± NA |
| Pain Right Now: Change at follow-up (n=48, 46) | 0.4 ± 2.64 | -0.0 ± 2.67 |
| Relief Pain Treatment (Tx): Baseline (n=226, 221) | 7.8 ± 12.09 | 6.9 ± 9.71 |
| Relief Pain Tx: Change at C2 D1 (n=164, 165) | 0.6 ± 13.96 | 0.4 ± 11.48 |
| Relief Pain Tx: Change at C3 D1 (n=122, 124) | -2.1 ± 13.10 | 0.1 ± 9.16 |
| Relief Pain Tx: Change at C4 D1 (n=88, 92) | -1.7 ± 13.51 | -0.9 ± 17.56 |
| Relief Pain Tx: Change at C5 D1 (n=59, 51) | -2.9 ± 16.35 | 1.8 ± 11.62 |
| Relief Pain Tx: Change at C6 D1 (n=34, 33) | -1.6 ± 11.90 | 0.5 ± 4.28 |
| Relief Pain Tx: Change at C7 D1 (n=21, 18) | 1.0 ± 2.78 | -3.2 ± 19.65 |
| Relief Pain Tx: Change at C8 D1 (n=10, 8) | -5.0 ± 21.20 | -11.6 ± 28.16 |
| Relief Pain Tx: Change at C9 D1 (n=5, 5) | -14.0 ± 28.99 | -16.6 ± 35.44 |
| Relief Pain Tx: Change at C10 D1 (n=1, 2) | 6.0 ± NA | 0.0 ± 1.41 |
| Relief Pain Tx: Change at C11 D1 (n=0, 1) | NA ± NA | 0.0 ± NA |
| Relief Pain Tx: Change at C12 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Relief Pain Tx: Change at C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Relief Pain Tx: Change at follow-up (n=43, 36) | 0.2 ± 3.82 | -0.4 ± 5.08 |
| General Activity: Baseline (n=243, 243) | 3.2 ± 3.11 | 3.0 ± 3.01 |
| General Activity: Change at C2 D1 (n=190, 193) | -0.6 ± 2.96 | -0.7 ± 2.55 |
| General Activity: Change at C3 D1 (n=135, 143) | -1.1 ± 3.47 | -0.7 ± 2.61 |
| General Activity: Change at C4 D1 (n=97, 109) | -0.4 ± 3.10 | -0.8 ± 2.53 |
| General Activity: Change at C5 D1 (n=66, 62) | -0.8 ± 3.64 | -0.5 ± 2.51 |
| General Activity: Change at C6 D1 (n=40, 41) | -0.6 ± 3.82 | -0.7 ± 2.62 |
| General Activity: Change at C7 D1 (n=25, 25) | -0.5 ± 2.87 | -0.4 ± 2.84 |
| General Activity: Change at C8 D1 (n=12, 12) | 0.1 ± 2.07 | -0.8 ± 2.70 |
| General Activity: Change at C9 D1 (n=6, 6) | -2.2 ± 2.71 | 0.3 ± 3.72 |
| General Activity: Change at C10 D1 (n=2, 3) | -2.5 ± 3.54 | 3.0 ± 5.29 |
| General Activity: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 1.0 ± NA |
| General Activity: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| General Activity: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -1.0 ± NA |
| General Activity: Change at follow-up (n=47, 44) | 1.0 ± 4.32 | 0.0 ± 3.63 |
| Mood: Baseline (n=243, 241) | 3.0 ± 2.92 | 2.8 ± 2.77 |
| Mood: Change at C2 D1 (n=191, 191) | -0.6 ± 2.74 | -0.2 ± 2.46 |
| Mood: Change at C3 D1 (n=135, 141) | -1.0 ± 3.39 | -0.5 ± 2.51 |
| Mood: Change at C4 D1 (n=98, 106) | -0.3 ± 3.22 | -0.9 ± 2.81 |
| Mood: Change at C5 D1 (n=66, 61) | -0.7 ± 3.66 | -0.9 ± 2.59 |
| Mood: Change at C6 D1 (n=40, 41) | -0.6 ± 3.23 | -0.8 ± 2.93 |
| Mood: Change at C7 D1 (n=25, 25) | 0.0 ± 2.54 | -0.2 ± 3.18 |
| Mood: Change at C8 D1 (n=12, 12) | 0.6 ± 1.31 | -1.1 ± 3.12 |
| Mood: Change at C9 D1 (n=6, 6) | -1.3 ± 1.97 | -0.8 ± 3.31 |
| Mood: Change at C10 D1 (n=2, 3) | -1.0 ± 1.41 | 3.3 ± 1.53 |
| Mood: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 5.0 ± NA |
| Mood: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Mood: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -3.0 ± NA |
| Mood: Change at follow-up (n=47, 44) | 0.9 ± 3.65 | 0.2 ± 3.62 |
| Walking Ability: Baseline (n=242, 243) | 2.2 ± 2.78 | 2.3 ± 2.81 |
| Walking Ability: Change at C2 D1 (n=189, 194) | 0.1 ± 2.84 | -0.1 ± 2.61 |
| Walking Ability: Change at C3 D1 (n=133, 143) | -0.2 ± 3.41 | -0.3 ± 2.52 |
| Walking Ability: Change at C4 D1 (n=97, 108) | 0.3 ± 3.32 | -0.4 ± 2.64 |
| Walking Ability: Change at C5 D1 (n=66, 62) | 0.1 ± 3.49 | -0.3 ± 2.37 |
| Walking Ability: Change at C6 D1 (n=41, 41) | 0.5 ± 2.86 | -0.2 ± 2.24 |
| Walking Ability: Change at C7 D1 (n=25, 25) | 1.1 ± 2.67 | -0.1 ± 2.42 |
| Walking Ability: Change at C8 D1 (n=12, 12) | 0.7 ± 2.46 | -1.3 ± 2.42 |
| Walking Ability: Change at C9 D1 (n=6, 6) | -1.0 ± 3.52 | 0.2 ± 4.62 |
| Walking Ability: Change at C10 D1 (n=2, 3) | -2.0 ± 2.83 | 1.3 ± 5.51 |
| Walking Ability: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 0.0 ± NA |
| Walking Ability: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Walking Ability: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -2.0 ± NA |
| Walking Ability: Change at follow-up (n=47, 45) | 0.9 ± 4.13 | 0.7 ± 3.27 |
| Normal Work: Baseline (n=240, 240) | 3.5 ± 3.34 | 3.2 ± 3.23 |
| Normal Work: Change at C2 D1 (n=187, 191) | -0.4 ± 3.24 | -0.1 ± 3.16 |
| Normal Work: Change at C3 D1 (n=133, 139) | -0.6 ± 3.33 | -0.4 ± 2.67 |
| Normal Work: Change at C4 D1 (n=96, 107) | -0.2 ± 3.15 | -0.7 ± 2.90 |
| Normal Work: Change at C5 D1 (n=65, 61) | -0.7 ± 3.86 | -0.6 ± 2.71 |
| Normal Work: Change at C6 D1 (n=39, 41) | 0.2 ± 3.62 | -0.2 ± 3.12 |
| Normal Work: Change at C7 D1 (n=25, 24) | 0.5 ± 2.76 | -0.4 ± 2.52 |
| Normal Work: Change at C8 D1 (n=12, 12) | -0.3 ± 3.70 | -0.1 ± 3.37 |
| Normal Work: Change at C9 D1 (n=6, 6) | -1.5 ± 3.51 | 3.5 ± 4.32 |
| Normal Work: Change at C10 D1 (n=2, 3) | -0.5 ± 0.71 | 1.3 ± 3.51 |
| Normal Work: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 2.0 ± NA |
| Normal Work: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Normal Work: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -2.0 ± NA |
| Normal Work: Change at follow-up (n=46, 43) | 1.0 ± 4.54 | 0.3 ± 3.90 |
| Relations: Baseline (n=244, 242) | 2.3 ± 2.93 | 1.9 ± 2.44 |
| Relations: Change at C2 D1 (n=190, 193) | -0.3 ± 2.82 | 0.0 ± 2.18 |
| Relations: Change at C3 D1 (n=136, 142) | -0.4 ± 3.81 | -0.0 ± 2.16 |
| Relations: Change at C4 D1 (n=98, 108) | -0.2 ± 3.36 | -0.1 ± 2.52 |
| Relations: Change at C5 D1 (n=66, 62) | -0.6 ± 3.11 | -0.1 ± 2.27 |
| Relations: Change at C6 D1 (n=40, 41) | -0.3 ± 4.01 | -0.1 ± 2.76 |
| Relations: Change at C7 D1 (n=25, 25) | 0.8 ± 3.32 | -0.7 ± 2.44 |
| Relations: Change at C8 D1 (n=12, 12) | 0.6 ± 2.61 | -0.9 ± 2.35 |
| Relations: Change at C9 D1 (n=6, 6) | -1.2 ± 2.93 | 0.8 ± 4.88 |
| Relations: Change at C10 D1 (n=2, 3) | 1.0 ± 1.41 | 2.7 ± 2.52 |
| Relations: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 2.0 ± NA |
| Relations: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Relations: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -2.0 ± NA |
| Relations: Change at follow-up (n=47, 45) | 0.7 ± 3.94 | 0.8 ± 3.56 |
| Sleep: Baseline (n=244, 242) | 3.3 ± 3.16 | 3.2 ± 3.17 |
| Sleep: Change at C2 D1 (n=191, 193) | -1.1 ± 3.36 | -0.9 ± 2.73 |
| Sleep: Change at C3 D1 (n=136, 142) | -1.6 ± 3.52 | -1.1 ± 2.89 |
| Sleep: Change at C4 D1 (n=98, 107) | -1.2 ± 3.29 | -1.2 ± 3.02 |
| Sleep: Change at C5 D1 (n=66, 62) | -1.3 ± 4.06 | -0.8 ± 3.37 |
| Sleep: Change at C6 D1(n=39, 41) | -1.5 ± 3.22 | -0.8 ± 3.62 |
| Sleep: Change at C7 D1 (n=25, 25) | -0.2 ± 3.61 | -0.6 ± 2.81 |
| Sleep: Change at C8 D1 (n=12, 12) | 0.6 ± 2.71 | -1.2 ± 3.51 |
| Sleep: Change at C9 D1 (n=6, 6) | -2.3 ± 3.20 | 0.3 ± 2.07 |
| Sleep: Change at C10 D1 (n=2, 3) | 1.0 ± 1.41 | 0.7 ± 3.51 |
| Sleep: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 4.0 ± NA |
| Sleep: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Sleep: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -5.0 ± NA |
| Sleep: Change at follow-up (n=47, 44) | 0.5 ± 3.65 | -0.3 ± 3.54 |
| Enjoyment of Life: Baseline (n=242, 240) | 3.5 ± 3.34 | 3.4 ± 3.17 |
| Enjoyment of Life: Change at C2 D1 (n=191, 191) | -0.6 ± 2.99 | -0.5 ± 2.89 |
| Enjoyment of Life: Change at C3 D1 (n=134, 142) | -0.7 ± 3.64 | -0.7 ± 2.77 |
| Enjoyment of Life: Change at C4 D1 (n=98, 107) | -0.6 ± 3.58 | -0.9 ± 2.70 |
| Enjoyment of Life: Change at C5 D1 (n=66, 62) | -0.6 ± 4.03 | -0.8 ± 3.07 |
| Enjoyment of Life: Change at C6 D1 (n=40, 41) | -0.4 ± 3.87 | -1.0 ± 3.17 |
| Enjoyment of Life: Change at C7 D1 (n=25, 25) | 0.4 ± 3.53 | -0.9 ± 2.28 |
| Enjoyment of Life: Change at C8 D1 (n=12, 12) | 0.8 ± 2.98 | -0.8 ± 2.53 |
| Enjoyment of Life: Change at C9 D1 (n=6, 6) | -0.5 ± 5.01 | 0.2 ± 2.86 |
| Enjoyment of Life: Change at C10 D1 (n=2, 3) | 0.5 ± 0.71 | 2.3 ± 5.51 |
| Enjoyment of Life: Change at C11 D1 (n=1, 1) | 0.0 ± NA | -1.0 ± NA |
| Enjoyment of Life: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Enjoyment of Life: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -4.0 ± NA |
| Enjoyment of Life: Change at follow-up (n=47, 43) | 0.2 ± 3.68 | -0.2 ± 3.99 |
| Combined Pain Intensity(PI): Baseline (n=248, 251) | 2.7 ± 1.98 | 2.6 ± 2.12 |
| Combined PI: Change at C2 D1 (n=196, 202) | -0.4 ± 1.97 | -0.5 ± 1.97 |
| Combined PI: Change at C3 D1 (n=140, 151) | -0.9 ± 2.15 | -0.6 ± 1.88 |
| Combined PI: Change at C4 D1 (n=99, 114) | -0.6 ± 2.19 | -0.5 ± 1.99 |
| Combined PI: Change at C5 D1 (n=69, 64) | -0.6 ± 2.46 | -0.6 ± 2.19 |
| Combined PI: Change at C6 D1 (n=41, 43) | -0.5 ± 1.92 | -0.6 ± 1.89 |
| Combined PI: Change at C7 D1 (n=25, 27) | -0.1 ± 1.48 | -0.4 ± 2.78 |
| Combined PI: Change at C8 D1 (n=12, 13) | 1.0 ± 2.01 | -0.9 ± 1.76 |
| Combined PI: Change at C9 D1 (n=6, 6) | -1.3 ± 1.51 | -0.8 ± 1.11 |
| Combined PI: Change at C10 D1 (n=2, 3) | -1.9 ± 2.69 | -0.1 ± 1.44 |
| Combined PI: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 1.5 ± NA |
| Combined PI: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Combined PI: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -3.0 ± NA |
| Combined PI:Change follow-up (n=48, 47) | 0.5 ± 2.34 | 0.2 ± 2.56 |
| Combined Pain Interference(Pf):Baseline(n=244,243) | 3.0 ± 2.64 | 2.8 ± 2.52 |
| Combined Pf: Change at C2 D1 (n=191, 194) | -0.5 ± 2.44 | -0.4 ± 1.97 |
| Combined Pf: Change at C3 D1 (n=136,143) | -0.8 ± 2.99 | -0.5 ± 2.01 |
| Combined Pf: Change at C4 D1 (n=98,109) | -0.4 ± 2.62 | -0.7 ± 2.12 |
| Combined Pf: Change at C5 D1 (n=66, 62) | -0.6 ± 3.18 | -0.6 ± 2.07 |
| Combined Pf: Change at C6 D1 (n=41, 41) | -0.4 ± 2.92 | -0.6 ± 2.38 |
| Combined Pf: Change at C7 D1 (n=25, 25) | 0.3 ± 2.32 | -0.5 ± 2.10 |
| Combined Pf: Change at C8 D1 (n=12, 12) | 0.4 ± 1.84 | -0.9 ± 2.15 |
| Combined Pf: Change at C9 D1 (n=6, 6) | -1.4 ± 2.69 | 0.7 ± 2.86 |
| Combined Pf: Change at C10 D1 (n=2, 3) | -0.5 ± 0.71 | 2.1 ± 2.90 |
| Combined Pf: Change at C11 D1 (n=1, 1) | 0.0 ± NA | 1.9 ± NA |
| Combined Pf: Change at C12 D1 (n=1, 0) | 0.0 ± NA | NA ± NA |
| Combined Pf: Change at C13 D1 (n=1, 1) | 0.0 ± NA | -2.7 ± NA |
| Combined Pf: Change at follow-up (n=47, 45) | 0.7 ± 3.55 | 0.3 ± 3.40 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| Units on a scale | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Baseline (n=289, 290) | 0.665 ± 0.2709 | 0.690 ± 0.2479 |
| Change at C2 D1 (n=231, 240) | 0.050 ± 0.2699 | 0.020 ± 0.2033 |
| Change at C3 D1 (n=171, 178) | 0.053 ± 0.2528 | 0.028 ± 0.2362 |
| Change at C4 D1 (n=128, 131) | 0.010 ± 0.2730 | 0.050 ± 0.2209 |
| Change at C5 D1 (n=94, 80) | 0.010 ± 0.2889 | 0.044 ± 0.2092 |
| Change at C6 D1 (n=57, 57) | 0.001 ± 0.2489 | 0.058 ± 0.2294 |
| Change at C7 D1 (n=37, 36) | 0.049 ± 0.1891 | 0.075 ± 0.1838 |
| Change at C8 D1 (n=17, 20) | -0.021 ± 0.2366 | 0.071 ± 0.2188 |
| Change at C9 D1 (n=9, 9) | 0.049 ± 0.1878 | 0.121 ± 0.3006 |
| Change at C10 D1 (n=3, 4) | 0.181 ± 0.2206 | 0.208 ± 0.3034 |
| Change at C11 D1 (n=1, 1) | 0.000 ± NA | 0.058 ± NA |
| Change at C12 D1 (n=1, 0) | 0.000 ± NA | NA ± NA |
| Change at C13 D1 (n=1, 1) | 0.000 ± NA | 0.470 ± NA |
| Change at follow-up (n=65, 73) | -0.148 ± 0.3637 | -0.080 ± 0.3243 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| Millimeter (mm) | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Baseline (n= 277, 281) | 60.6 ± 23.67 | 62.6 ± 23.09 |
| Change at Cycle 2 Day 1 (n= 223, 226) | 1.0 ± 19.64 | -0.4 ± 20.42 |
| Change at Cycle 3 Day 1 (n= 161, 171) | 2.6 ± 22.30 | 1.1 ± 20.25 |
| Change at Cycle 4 Day 1 (n=122, 128) | 0.5 ± 22.38 | 3.2 ± 19.81 |
| Change at Cycle 5 Day 1 (n= 90, 79) | -0.3 ± 22.83 | 1.9 ± 19.40 |
| Change at Cycle 6 Day 1 (n= 56, 56) | 1.0 ± 24.63 | 3.7 ± 21.84 |
| Change at Cycle 7 Day 1 (n= 36, 35) | 2.6 ± 25.82 | 4.1 ± 22.52 |
| Change at Cycle 8 Day 1 (n= 16, 19) | 3.8 ± 23.21 | 9.6 ± 28.55 |
| Change at Cycle 9 Day 1 (n= 9, 9) | 22.2 ± 24.93 | 7.7 ± 20.00 |
| Change at Cycle 10 Day 1 (n= 3, 4) | 20.0 ± 26.46 | 6.3 ± 24.62 |
| Change at Cycle 11 Day 1 (n= 1, 1) | 0.0 ± NA | 30.0 ± NA |
| Change at Cycle 12 Day 1 (n= 1, 0) | 0.0 ± NA | NA ± NA |
| Change at Cycle 13 Day 1 (n= 1, 1) | 0.0 ± NA | 36.0 ± NA |
| Change at follow-up (n= 62, 68) | -6.3 ± 24.07 | -4.8 ± 22.79 |
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Gemcitabine | — | 108/304 (35.5%) | 276/304 (90.8%) |
| Placebo + Gemcitabine | — | 102/309 (33%) | 276/309 (89.3%) |
| Event | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| Disease progressionGeneral disorders | 9/304 | 15/309 |
| Abdominal painGastrointestinal disorders | 14/304 | 10/309 |
| PyrexiaGeneral disorders | 13/304 | 5/309 |
| VomitingGastrointestinal disorders | 9/304 | 11/309 |
| AstheniaGeneral disorders | 8/304 | 2/309 |
| NauseaGastrointestinal disorders | 7/304 | 3/309 |
| CholangitisHepatobiliary disorders | 7/304 | 3/309 |
| Decreased appetiteMetabolism and nutrition disorders | 7/304 | 4/309 |
| JaundiceHepatobiliary disorders | 6/304 | 4/309 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/304 | 6/309 |
| Event | Axitinib + Gemcitabine | Placebo + Gemcitabine |
|---|---|---|
| NauseaGastrointestinal disorders | 138/304 | 112/309 |
| FatigueGeneral disorders | 125/304 | 113/309 |
| Decreased appetiteMetabolism and nutrition disorders | 115/304 | 87/309 |
| DiarrhoeaGastrointestinal disorders | 96/304 | 64/309 |
| VomitingGastrointestinal disorders | 91/304 | 95/309 |
| ConstipationGastrointestinal disorders | 88/304 | 91/309 |
| HypertensionVascular disorders | 84/304 | 26/309 |
| NeutropeniaBlood and lymphatic system disorders | 73/304 | 53/309 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 68/304 | 12/309 |
| Abdominal painGastrointestinal disorders | 54/304 | 52/309 |
| Age, Customized(Participants) | Axitinib + Gemcitabine | Placebo + Gemcitabine | Total |
|---|---|---|---|
| Less than 65 years | 203 | 179 | 382 |
| Greater than or equal to 65 years | 111 | 137 | 248 |
| Sex: Female, Male(Participants) | Axitinib + Gemcitabine | Placebo + Gemcitabine | Total |
|---|---|---|---|
| Female | 123 | 128 | 251 |
| Male | 191 | 188 | 379 |
Showing the first 100 of 205 sites across 24 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2007, a primary completion of Jan 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 3 years 6 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib
Carcinoma, Pancreatic Ductal →